Hubei Jumpcan Pharmaceutical restricts stock option exercise

Hubei Jumpcan Pharmaceutical Co., Ltd. has announced a restricted exercise period for stock options initially granted under its 2022 Restricted Stock and Stock Option Incentive Plan. This decision aligns with the "Administrative Measures for Equity Incentives of Listed Companies" and "Self-Regulatory Guidelines No. 2 for Listed Companies on the Shanghai Stock Exchange – Business Handling," as well as the company's 2025 third-quarter report disclosure schedule.

The first exercise period for the initially granted stock options is from October 15, 2025, to September 7, 2026. However, a specific restricted exercise period has been set from October 23, 2025, to October 27, 2025. During this five-day window, all incentive recipients will be prohibited from exercising their stock options.

The company will promptly handle all related restriction applications with China Securities Depository and Clearing Corporation Limited, Shanghai Branch, in accordance with relevant regulations. This announcement was made by the board of directors of Hubei Jumpcan Pharmaceutical Co., Ltd. on October 15, 2025.